方法证据记录
Bayesian Phase II Clinical Trial
A Bayesian Phase II clinical trial applies Bayesian statistical inference to the standard Phase II objective of evaluating whether an experimental treatment shows sufficient early-phase efficacy to justify progression to a Phase III trial. By combining prior information with accumulating trial data, it enables principled interim monitoring, flexible stopping rules, and updated probability statements about treatment effect — all without the multiple-testing penalties that burden frequentist sequential designs.
源记录
引文逐字复制自方法源记录。这些引文不代表任何层级的验证。
Bayesian Phase II Clinical Trial Design
分类方法记录 · process-pipeline / epidemiology
- Thall, P. F., & Simon, R. (1994). Practical Bayesian guidelines for phase IIB clinical trials. Biometrics, 50(2), 337–349. · DOI 10.2307/2533377
- Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36. · DOI 10.1038/nrd1927
精选声明
声明已持久化到证据分类账中，每个声明都有自己的评估。
尚无精选声明
当分类账中没有声明时，此视图不会自行创建声明评估。
相关方法
从方法图中生成，显示为机器建议的关系 — 不推断任何证据声明。